Osimertinib

[MAF] Osimertinib Tablet 40 mg, 80 mg

1. Treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR TKI therapy. For patients with isolated brain metastases who are clinically ineligible for re-biopsy and where T790M cannot be confirmed, osimertinib may be used until progression.

[MSHL] Osimertinib Tablet 40 mg, 80 mg

1. For newly diagnosed locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer, including patients who have developed intolerance to another EGFR tyrosine kinase inhibitor of a severity necessitating permanent treatment withdrawal.

2. Treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR TKI therapy. For patients with isolated brain metastases who are clinically ineligible for re-biopsy and where T790M cannot be confirmed, osimertinib may be used until progression.

3. Adjuvant treatment after tumour resection in patients with stage IB to IIIA non-small-cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. Treatment should be continued until disease recurrence or unacceptable toxicity or for a maximum of 3 years.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

01/02/2024 Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer

The Ministry of Health’s Drug Advisory Committee has recommended:

• Osimertinib 40 mg and 80 mg tablets for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC) in patients whose disease has progressed on or after EGFR TKI therapy. For patients with isolated brain metastases who are clinically ineligible for re-biopsy and where T790M cannot be confirmed, osimertinib may be used until progression.

Subsidy status

[R] Osimertinib 40 mg and 80 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

[NR] MAF assistance does not apply to osimertinib 40 mg or 80 mg tablets when used for adjuvant treatment of EGFR mutation-positive NSCLC after tumour resection, or for newly diagnosed locally advanced or metastatic EGFR mutation-positive NSCLC.

Clinical indications, subsidy class and MediShield Life claim limits for osimertinib are provided in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration